Gene Polymorphism of IL17 and IL 23

NCT04948515 | Completed

• 1 other identifier: Soh-Med-21-04-35
• Study Type: observational
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

rates are in such considerable amount among large population base. The pathogenesis of COVID-19 implicates a potent inflammatory response, involving a complex group of mediators including interleukins. These pleiotropic cytokines are secreted at the region of inflammation and released into the circulation by a variety of different cell types, including macrophages, lymphocytes, endothelial cells, epithelial cells during sepsis and acute organ injuries. There has recently found a number of studies reporting that the cytokine storms take part in the course of COVID-19

Conditions

COVID-19 Respiratory Infection

Outcome Measures

Primary Outcomes (3)

• genotyping of IL 17

  real time pcr detection of different genotypes

  3-6-2021 to 30-8-2021

• genotyping of IL 23

  real time pcr detection of different genotypes

  3-6-2021 to 30-8-2021

• estimation of serum level of IL 17

  measuring serum level of IL 17 by ELISA

  3-6-2021 to 30-8-2021

Study Arms (2)

group 1 patients with severe covid 19 respiratory infections

Patients with severe covid 19 admitted to ICU, blood samples will be collected for testing different genotypes and serum level of IL 17

Diagnostic Test: laboratory test

group 2 patients with non severe covid 19 respiratory infections

Patients with nonsevere covid 19 admitted to the internal ward, blood samples will be collected for testing different genotypes and serum level of IL 17

Diagnostic Test: laboratory test

Interventions

laboratory test DIAGNOSTIC_TEST

genotyping of IL 17 and IL23

group 1 patients with severe covid 19 respiratory infections; group 2 patients with non severe covid 19 respiratory infections

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

group 1 patients with covid 19 with severe infections admitted at ICU group 2 patients with covid 19 with nonsevere infections admitted at internal wards

You may qualify if:

• Patients with Covid19 positive PCR

You may not qualify if:

• Patients with Covid19 clinical criteria not confirmed by PCR

Sponsors & Collaborators

• Sohag University: lead

Study Sites (1)

Sohag University

Sohag, 82733, Egypt

Location

Biospecimen

Retention: SAMPLES WITH DNA

whole blood collected on EDITA tubes for genotyping by ELISA and serum blood on plane tubes for ELISA

MeSH Terms

Interventions

Clinical Laboratory Techniques

Intervention Hierarchy (Ancestors)

Diagnostic Techniques and Procedures; Diagnosis; Investigative Techniques

Study Officials

• N S shafik, lecturer

  Sohag University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Target Duration: 4 Months
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: lecturer

Study Record Dates

• First Submitted: June 24, 2021
• First Posted: July 2, 2021
• Study Start: June 3, 2021
• Primary Completion: November 30, 2021
• Study Completion: December 3, 2021
• Last Updated: October 25, 2022

Record last verified: 2022-10

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)